NIMG-50. INITIAL EXPERIENCE: DETECTION OF ABERRANT HYPERPOLARIZED [1-13C]PYRUVATE METABOLISM IN PATIENTS WITH GBM PRIOR TO RESECTION. Read more about NIMG-50. INITIAL EXPERIENCE: DETECTION OF ABERRANT HYPERPOLARIZED [1-13C]PYRUVATE METABOLISM IN PATIENTS WITH GBM PRIOR TO RESECTION.
NIMG-47. METABOLIC CHARACTERIZATION OF IDH MUTANT LOWER GRADE GLIOMA USING SPECTROSCOPIC IMAGING OPTIMIZED FOR 2-HYDROXYGLUTARATE DETECTION. Read more about NIMG-47. METABOLIC CHARACTERIZATION OF IDH MUTANT LOWER GRADE GLIOMA USING SPECTROSCOPIC IMAGING OPTIMIZED FOR 2-HYDROXYGLUTARATE DETECTION.
A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. Read more about A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study.
Recurrent tumor and treatment-induced effects have different MR signatures in contrast enhancing and non-enhancing lesions of high-grade gliomas. Read more about Recurrent tumor and treatment-induced effects have different MR signatures in contrast enhancing and non-enhancing lesions of high-grade gliomas.
Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival. Read more about Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival.
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Read more about Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.
Exosomal PD-L1 induces immunosuppressive nonclassical monocytes. Read more about Exosomal PD-L1 induces immunosuppressive nonclassical monocytes.
A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE). Read more about A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. Read more about Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients.
Betacellulin drives therapy resistance in glioblastoma. Read more about Betacellulin drives therapy resistance in glioblastoma.
